# Nicholas P Restifo

## List of Publications by Citations



| | | | |
|---|---|---|---|
| 300 papers | 60,657 citations | 118 h-index | 245 g-index |
| 319 ext. papers | 68,766 ext. citations | 14.8 avg, IF | 7.68 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 300 | Cancer immunotherapy: moving beyond current vaccines. *Nature Medicine*, **2004**, 10, 909-15 | 50.5 | 2369 |
| 299 | Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. *Science*, **2002**, 298, 850-4 | 33.3 | 2293 |
| 298 | Cancer regression in patients after transfer of genetically engineered lymphocytes. *Science*, **2006**, 314, 126-9 | 33.3 | 2001 |
| 297 | Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. *Nature Medicine*, **1998**, 4, 321-7 | 50.5 | 1539 |
| 296 | Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. *Clinical Cancer Research*, **2011**, 17, 4550-7 | 12.9 | 1434 |
| 295 | Adoptive cell transfer as personalized immunotherapy for human cancer. *Science*, **2015**, 348, 62-8 | 33.3 | 1420 |
| 294 | Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. *Proceedings of the National Academy of Sciences of the United States of America*, **2003**, 100, 8372-7 | 11.5 | 1325 |
| 293 | Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. *Journal of Clinical Oncology*, **2005**, 23, 2346-57 | 2.2 | 1294 |
| 292 | Adoptive immunotherapy for cancer: harnessing the T cell response. *Nature Reviews Immunology*, **2012**, 12, 269-81 | 36.5 | 1192 |
| 291 | Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. *Journal of Clinical Oncology*, **2011**, 29, 917-24 | 2.2 | 1185 |
| 290 | Adoptive cell transfer: a clinical path to effective cancer immunotherapy. *Nature Reviews Cancer*, **2008**, 8, 299-308 | 31.3 | 1179 |
| 289 | A human memory T cell subset with stem cell-like properties. *Nature Medicine*, **2011**, 17, 1290-7 | 50.5 | 1153 |
| 288 | Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. *Blood*, **2009**, 114, 535-46 | 2.2 | 1077 |
| 287 | Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. *Journal of Clinical Oncology*, **2008**, 26, 5233-9 | 2.2 | 1045 |
| 286 | Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. *Journal of Clinical Oncology*, **2005**, 23, 6043-53 | 2.2 | 880 |
| 285 | Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. *Journal of Experimental Medicine*, **2005**, 202, 907-12 | 16.6 | 809 |
| 284 | Natural selection of tumor variants in the generation of "tumor escape" phenotypes. *Nature Immunology*, **2002**, 3, 999-1005 | 19.1 | 799 |

| | | | |
|---|---|---|---|
| 283 | Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. *Journal of Immunotherapy*, **2013**, 36, 133-51 | 5 | 758 |
| 282 | Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. *Journal of Experimental Medicine*, **2003**, 198, 569-80 | 16.6 | 754 |
| 281 | Adoptive immunotherapy for cancer: building on success. *Nature Reviews Immunology*, **2006**, 6, 383-93 | 36.5 | 724 |
| 280 | Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. *Journal of Clinical Investigation*, **2005**, 115, 1616-26 | 15.9 | 701 |
| 279 | T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. *Molecular Therapy*, **2011**, 19, 620-6 | 11.7 | 693 |
| 278 | Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2005**, 102, 9571-6 | 11.5 | 692 |
| 277 | Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. *Nature Medicine*, **2009**, 15, 808-13 | 50.5 | 675 |
| 276 | Tumor-specific Th17-polarized cells eradicate large established melanoma. *Blood*, **2008**, 112, 362-73 | 2.2 | 615 |
| 275 | CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. *Journal of Immunology*, **2005**, 174, 2591-601 | 5.3 | 595 |
| 274 | Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. *Journal of Experimental Medicine*, **2005**, 201, 139-48 | 16.6 | 576 |
| 273 | T helper 17 cells promote cytotoxic T cell activation in tumor immunity. *Immunity*, **2009**, 31, 787-98 | 32.3 | 567 |
| 272 | Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. *Journal of Experimental Medicine*, **2010**, 207, 637-50 | 16.6 | 559 |
| 271 | Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function. *Journal of Clinical Investigation*, **2013**, 123, 4479-88 | 15.9 | 535 |
| 270 | Human memory T cells: generation, compartmentalization and homeostasis. *Nature Reviews Immunology*, **2014**, 14, 24-35 | 36.5 | 513 |
| 269 | Predominant role for directly transfected dendritic cells in antigen presentation to CD8+ T cells after gene gun immunization. *Journal of Experimental Medicine*, **1998**, 188, 1075-82 | 16.6 | 495 |
| 268 | A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. *Clinical Cancer Research*, **2015**, 21, 1019-27 | 12.9 | 494 |
| 267 | Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer. *Cancer Research*, **2010**, 70, 6171-80 | 10.1 | 473 |
| 266 | Identification of essential genes for cancer immunotherapy. *Nature*, **2017**, 548, 537-542 | 50.4 | 460 |

| | | | |
|---|---|---|---|
| 265 | T(H)17 cells in tumour immunity and immunotherapy. *Nature Reviews Immunology*, **2010**, 10, 248-56 | 36.5 | 460 |
| 264 | Identification of a CD11b+/Gr-1+/CD31+ myeloid progenitor capable of activating or suppressing CD8+T cells. *Blood*, **2000**, 96, 3838-3846 | 2.2 | 442 |
| 263 | IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 1969-74 | 11.5 | 441 |
| 262 | Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. *Journal of Immunology*, **2005**, 175, 6169-76 | 5.3 | 391 |
| 261 | gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. *Journal of Experimental Medicine*, **1998**, 188, 277-86 | 16.6 | 391 |
| 260 | Defining 'T cell exhaustion'. *Nature Reviews Immunology*, **2019**, 19, 665-674 | 36.5 | 387 |
| 259 | Paths to stemness: building the ultimate antitumour T cell. *Nature Reviews Cancer*, **2012**, 12, 671-84 | 31.3 | 376 |
| 258 | CD8+ T-cell memory in tumor immunology and immunotherapy. *Immunological Reviews*, **2006**, 211, 214-24 | 11.3 | 369 |
| 257 | Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. *Journal of Clinical Investigation*, **2007**, 117, 2197-204 | 15.9 | 365 |
| 256 | Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. *Journal of Clinical Oncology*, **2015**, 33, 1543-50 | 2.2 | 356 |
| 255 | Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. *Trends in Immunology*, **2005**, 26, 111-7 | 14.4 | 346 |
| 254 | IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. *Blood*, **2008**, 111, 5326-33 | 2.2 | 320 |
| 253 | Th17 cells are long lived and retain a stem cell-like molecular signature. *Immunity*, **2011**, 35, 972-85 | 32.3 | 316 |
| 252 | Ionic immune suppression within the tumour microenvironment limits T cell effector function. *Nature*, **2016**, 537, 539-543 | 50.4 | 313 |
| 251 | Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 17469-74 | 11.5 | 302 |
| 250 | Classification of current anticancer immunotherapies. *Oncotarget*, **2014**, 5, 12472-508 | 3.3 | 301 |
| 249 | Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma. *Journal of Experimental Medicine*, **2010**, 207, 651-67 | 16.6 | 301 |
| 248 | Cancer therapy using a self-replicating RNA vaccine. *Nature Medicine*, **1999**, 5, 823-7 | 50.5 | 275 |

| | | | |
|---|---|---|---|
| 247 | Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. *Journal of Experimental Medicine*, **2001**, 194, 481-9 | 16.6 | 274 |
| 246 | BACH2 represses effector programs to stabilize T(reg)-mediated immune homeostasis. *Nature*, **2013**, 498, 506-10 | 50.4 | 264 |
| 245 | Essentials of Th17 cell commitment and plasticity. *Blood*, **2013**, 121, 2402-14 | 2.2 | 262 |
| 244 | Acquired resistance to immunotherapy and future challenges. *Nature Reviews Cancer*, **2016**, 16, 121-6 | 31.3 | 260 |
| 243 | Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go?. *Nature Clinical Practice Oncology*, **2006**, 3, 668-81 | | 258 |
| 242 | Cellular constituents of immune escape within the tumor microenvironment. *Cancer Research*, **2012**, 72, 3125-30 | 10.1 | 248 |
| 241 | DNA and RNA-based vaccines: principles, progress and prospects. *Vaccine*, **1999**, 18, 765-77 | 4.1 | 248 |
| 240 | Super-enhancers delineate disease-associated regulatory nodes in T cells. *Nature*, **2015**, 520, 558-62 | 50.4 | 247 |
| 239 | Prospects for gene-engineered T cell immunotherapy for solid cancers. *Nature Medicine*, **2016**, 22, 26-36 | 50.5 | 243 |
| 238 | Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. *Nature Medicine*, **2003**, 9, 33-9 | 50.5 | 240 |
| 237 | Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. *Blood*, **2010**, 116, 3875-86 | 2.2 | 239 |
| 236 | IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. *Journal of Clinical Investigation*, **2011**, 121, 4746-57 | 15.9 | 238 |
| 235 | Distinct Regulation of Th17 and Th1 Cell Differentiation by Glutaminase-Dependent Metabolism. *Cell*, **2018**, 175, 1780-1795.e19 | 56.2 | 236 |
| 234 | CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. *Clinical Cancer Research*, **2010**, 16, 6122-31 | 12.9 | 231 |
| 233 | High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation. *Molecular Therapy*, **2006**, 13, 151-9 | 11.7 | 229 |
| 232 | Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. *Blood*, **2011**, 117, 808-14 | 2.2 | 226 |
| 231 | B16 as a mouse model for human melanoma. *Current Protocols in Immunology*, **2001**, Chapter 20, Unit 20.1 | 4 | 224 |
| 230 | Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia. *Journal of Experimental Medicine*, **2013**, 210, 1125-35 | 16.6 | 223 |

| | | | |
|---|---|---|---|
| 229 | Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape. *Nature Medicine*, **2000**, 6, 493-5 | 50.5 | 222 |
| 228 | Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma. *Journal of Clinical Oncology*, **2016**, 34, 2389-97 | 2.2 | 220 |
| 227 | Therapeutic cancer vaccines: are we there yet?. *Immunological Reviews*, **2011**, 239, 27-44 | 11.3 | 218 |
| 226 | Superior T memory stem cell persistence supports long-lived T cell memory. *Journal of Clinical Investigation*, **2013**, 123, 594-9 | 15.9 | 216 |
| 225 | Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma. *Clinical Cancer Research*, **2015**, 21, 2278-88 | 12.9 | 214 |
| 224 | Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics. *Cancer Research*, **2015**, 75, 296-305 | 10.1 | 212 |
| 223 | Mitochondrial Membrane Potential Identifies Cells with Enhanced Stemness for Cellular Therapy. *Cell Metabolism*, **2016**, 23, 63-76 | 24.6 | 210 |
| 222 | Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy. *Cell Metabolism*, **2017**, 26, 94-109 | 24.6 | 206 |
| 221 | MicroRNA-155 is required for effector CD8+ T cell responses to virus infection and cancer. *Immunity* , **2013**, 38, 742-53 | 32.3 | 204 |
| 220 | Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice. *Clinical Cancer Research*, **2011**, 17, 5343-52 | 12.9 | 204 |
| 219 | Local delivery of interleukin-12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice. *Clinical Cancer Research*, **2012**, 18, 1672-83 | 12.9 | 199 |
| 218 | High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens. *Journal of Immunology*, **2003**, 171, 3287-95 | 5.3 | 198 |
| 217 | Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells. *Journal of Immunotherapy*, **2010**, 33, 1-7 | 5 | 197 |
| 216 | T cell stemness and dysfunction in tumors are triggered by a common mechanism. *Science*, **2019**, 363, | 33.3 | 196 |
| 215 | Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy?. *Journal of Immunotherapy*, **2012**, 35, 651-60 | 5 | 195 |
| 214 | Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. *Cancer Research*, **2010**, 70, 6725-34 | 10.1 | 187 |
| 213 | Suppressors of cytokine signaling (SOCS) in T cell differentiation, maturation, and function. *Trends in Immunology*, **2009**, 30, 592-602 | 14.4 | 187 |
| 212 | Adoptive immunotherapy of cancer using CD4(+) T cells. *Current Opinion in Immunology*, **2009**, 21, 200-8 | 7.8 | 183 |

| | | | |
|---|---|---|---|
| 211 | Molecular characterization of defective antigen processing in human prostate cancer. *Journal of the National Cancer Institute*, **1995**, 87, 280-5 | 9.7 | 182 |
| 210 | Epigenetic control of CD8 T cell differentiation. *Nature Reviews Immunology*, **2018**, 18, 340-356 | 36.5 | 181 |
| 209 | Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. *Clinical Cancer Research*, **2008**, 14, 5610-8 | 12.9 | 179 |
| 208 | Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity. *Cancer Research*, **2006**, 66, 4904-12 | 10.1 | 179 |
| 207 | Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment. *Molecular Therapy*, **2011**, 19, 751-9 | 11.7 | 174 |
| 206 | Type 17 CD8+ T cells display enhanced antitumor immunity. *Blood*, **2009**, 114, 596-9 | 2.2 | 174 |
| 205 | CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2. *Journal of Immunotherapy*, **2005**, 28, 120-8 | 5 | 165 |
| 204 | Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma. *Journal of Clinical Oncology*, **2013**, 31, 2152-9 | 2.2 | 163 |
| 203 | Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. *Journal of Clinical Investigation*, **2010**, 120, 3953-68 | 15.9 | 163 |
| 202 | Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells. *Journal of Clinical Investigation*, **2007**, 117, 492-501 | 15.9 | 155 |
| 201 | Memory T cell-driven differentiation of naive cells impairs adoptive immunotherapy. *Journal of Clinical Investigation*, **2016**, 126, 318-34 | 15.9 | 152 |
| 200 | Oxygen Sensing by T Cells Establishes an Immunologically Tolerant Metastatic Niche. *Cell*, **2016**, 166, 1117-1131.e14 | 56.2 | 151 |
| 199 | Cutting edge: CD4+ T cell control of CD8+ T cell reactivity to a model tumor antigen. *Journal of Immunology*, **2000**, 164, 562-5 | 5.3 | 146 |
| 198 | Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapy. *Journal of Experimental Medicine*, **2000**, 191, 1221-32 | 16.6 | 145 |
| 197 | Reassessing target antigens for adoptive T-cell therapy. *Nature Biotechnology*, **2013**, 31, 999-1008 | 44.5 | 143 |
| 196 | T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, 6973-8 | 11.5 | 143 |
| 195 | Lineage relationship of effector and memory T cells. *Current Opinion in Immunology*, **2013**, 25, 556-63 | 7.8 | 139 |
| 194 | Identification, isolation and in vitro expansion of human and nonhuman primate T stem cell memory cells. *Nature Protocols*, **2013**, 8, 33-42 | 18.8 | 138 |

| | | | |
|---|---|---|---|
| 193 | Regulation of nucleosome landscape and transcription factor targeting at tissue-specific enhancers by BRG1. *Genome Research*, **2011**, 21, 1650-8 | 9.7 | 138 |
| 192 | Repression of the DNA-binding inhibitor Id3 by Blimp-1 limits the formation of memory CD8+ T cells. *Nature Immunology*, **2011**, 12, 1230-7 | 19.1 | 136 |
| 191 | BACH2 regulates CD8(+) T cell differentiation by controlling access of AP-1 factors to enhancers. *Nature Immunology*, **2016**, 17, 851-860 | 19.1 | 136 |
| 190 | Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors. *Journal of the National Cancer Institute*, **1997**, 89, 1595-601 | 9.7 | 133 |
| 189 | Immune evasion by murine melanoma mediated through CC chemokine receptor-10. *Journal of Experimental Medicine*, **2003**, 198, 1337-47 | 16.6 | 133 |
| 188 | A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer. *Journal of Immunology*, **2011**, 186, 685-96 | 5.3 | 129 |
| 187 | Building better vaccines: how apoptotic cell death can induce inflammation and activate innate and adaptive immunity. *Current Opinion in Immunology*, **2000**, 12, 597-603 | 7.8 | 128 |
| 186 | Wnt/beta-catenin signaling in T-cell immunity and cancer immunotherapy. *Clinical Cancer Research*, **2010**, 16, 4695-701 | 12.9 | 123 |
| 185 | De novo induction of a cancer/testis antigen by 5-aza-2'-deoxycytidine augments adoptive immunotherapy in a murine tumor model. *Cancer Research*, **2006**, 66, 1105-13 | 10.1 | 123 |
| 184 | Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers. *Journal of Clinical Investigation*, **2019**, 129, 1109-1114 | 15.9 | 119 |
| 183 | Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules. *Journal of Immunology*, **2000**, 165, 1153-9 | 5.3 | 118 |
| 182 | Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor-transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma. *Journal of Immunotherapy*, **2019**, 42, 126-135 | 5 | 116 |
| 181 | Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors. *Cancer Immunology Research*, **2016**, 4, 204-14 | 12.5 | 115 |
| 180 | A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer. *Human Gene Therapy*, **2014**, 25, 1003-12 | 4.8 | 113 |
| 179 | Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice. *Journal of Immunology*, **2000**, 164, 3535-42 | 5.3 | 111 |
| 178 | Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens. *Journal of Immunotherapy*, **2003**, 26, 349-56 | 5 | 109 |
| 177 | Bcl-2 overexpression enhances tumor-specific T-cell survival. *Cancer Research*, **2005**, 65, 2001-8 | 10.1 | 109 |
| 176 | Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 8061-6 | 11.5 | 105 |

| | | | |
|---|---|---|---|
| 175 | Dendritic cells strongly boost the antitumor activity of adoptively transferred T cells in vivo. *Cancer Research*, **2004**, 64, 6783-90 | 10.1 | 105 |
| 174 | Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity. *Nature Medicine*, **2010**, 16, 339-45 | 50.5 | 102 |
| 173 | Consensus nomenclature for CD8 T cell phenotypes in cancer. *OncoImmunology*, **2015**, 4, e998538 | 7.2 | 101 |
| 172 | Toll-like receptors in tumor immunotherapy. *Clinical Cancer Research*, **2007**, 13, 5280-9 | 12.9 | 101 |
| 171 | Vaccine-stimulated, adoptively transferred CD8+ T cells traffic indiscriminately and ubiquitously while mediating specific tumor destruction. *Journal of Immunology*, **2004**, 173, 7209-16 | 5.3 | 100 |
| 170 | Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen. *Human Gene Therapy*, **2003**, 14, 709-14 | 4.8 | 99 |
| 169 | Molecular mechanisms used by tumors to escape immune recognition: immunogenetherapy and the cell biology of major histocompatibility complex class I. *Journal of Immunotherapy*, **1993**, 14, 182-90 | 5 | 97 |
| 168 | Interleukin-2-dependent mechanisms of tolerance and immunity in vivo. *Journal of Immunology*, **2006**, 176, 5255-66 | 5.3 | 96 |
| 167 | Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy. *JCI Insight*, **2017**, 2, | 9.9 | 94 |
| 166 | Retinoic acid controls the homeostasis of pre-cDC-derived splenic and intestinal dendritic cells. *Journal of Experimental Medicine*, **2013**, 210, 1961-76 | 16.6 | 93 |
| 165 | Poor immunogenicity of a self/tumor antigen derives from peptide/MHC-I instability and is independent of tolerance. *Journal of Clinical Investigation*, **2004**, 114, 551-559 | 15.9 | 93 |
| 164 | Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100. *Journal of Immunotherapy*, **1997**, 20, 15-25 | 5 | 92 |
| 163 | The Bone Marrow Protects and Optimizes Immunological Memory during Dietary Restriction. *Cell*, **2019**, 178, 1088-1101.e15 | 56.2 | 91 |
| 162 | Developing neoantigen-targeted T cell-based treatments for solid tumors. *Nature Medicine*, **2019**, 25, 1488-1499 | 50.5 | 90 |
| 161 | Increased immunogenicity of an anchor-modified tumor-associated antigen is due to the enhanced stability of the peptide/MHC complex: implications for vaccine design. *Journal of Immunology*, **2005** , 174, 4812-20 | 5.3 | 89 |
| 160 | The interplay of effector and regulatory T cells in cancer. *Current Opinion in Immunology*, **2015**, 33, 101-11 | 7.8 | 88 |
| 159 | Less is more: lymphodepletion followed by hematopoietic stem cell transplant augments adoptive T-cell-based anti-tumor immunotherapy. *Current Opinion in Immunology*, **2005**, 17, 195-201 | 7.8 | 88 |
| 158 | Uncoupling T-cell expansion from effector differentiation in cell-based immunotherapy. *Immunological Reviews*, **2014**, 257, 264-276 | 11.3 | 87 |

| | | | |
|---|---|---|---|
| 157 | Immune selection of hot-spot beta 2-microglobulin gene mutations, HLA-A2 allospecificity loss, and antigen-processing machinery component down-regulation in melanoma cells derived from recurrent metastases following immunotherapy. *Journal of Immunology*, **2005**, 174, 1462-71 | 5.3 | 86 |
| 156 | Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance. *Journal of Experimental Medicine*, **2015**, 212, 2095-113 | 16.6 | 85 |
| 155 | Tumor-specific CD4+ T cells maintain effector and memory tumor-specific CD8+ T cells. *European Journal of Immunology*, **2014**, 44, 69-79 | 6.1 | 83 |
| 154 | miR-155 augments CD8+ T-cell antitumor activity in lymphoreplete hosts by enhancing responsiveness to homeostatic □ cytokines. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, 476-81 | 11.5 | 80 |
| 153 | BACH2 immunodeficiency illustrates an association between super-enhancers and haploinsufficiency. *Nature Immunology*, **2017**, 18, 813-823 | 19.1 | 79 |
| 152 | Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model. *Vaccine*, **1997**, 15, 387-94 | 4.1 | 79 |
| 151 | Engineering the immune response to "self" for effective cancer immunotherapy **2014**, 2, P22 | | 78 |
| 150 | Inhibition of the T cell oxygen sensing machinery promotes anti-tumor efficacy **2015**, 3, | | 78 |
| 149 | Extrathymic generation of tumor-specific T cells from genetically engineered human hematopoietic stem cells via Notch signaling. *Cancer Research*, **2007**, 67, 2425-9 | 10.1 | 78 |
| 148 | Dendritic cells infected with poxviruses encoding MART-1/Melan A sensitize T lymphocytes in vitro. *Journal of Immunotherapy*, **1997**, 20, 276-86 | 5 | 77 |
| 147 | Structures of MART-126/27-35 Peptide/HLA-A2 complexes reveal a remarkable disconnect between antigen structural homology and T cell recognition. *Journal of Molecular Biology*, **2007**, 372, 1123-36 | 6.5 | 77 |
| 146 | Interleukin-7-dependent expansion and persistence of melanoma-specific T cells in lymphodepleted mice lead to tumor regression and editing. *Cancer Research*, **2005**, 65, 10569-77 | 10.1 | 77 |
| 145 | Intensity of the vaccine-elicited immune response determines tumor clearance. *Journal of Immunology*, **2002**, 168, 338-47 | 5.3 | 77 |
| 144 | Simultaneous targeting of tumor antigens and the tumor vasculature using T lymphocyte transfer synergize to induce regression of established tumors in mice. *Cancer Research*, **2013**, 73, 3371-80 | 10.1 | 75 |
| 143 | Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant. *Journal of Immunology*, **2006**, 176, 5213-22 | 5.3 | 72 |
| 142 | Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting. *Clinical Cancer Research*, **2017**, 23, 2478-2490 | 12.9 | 71 |
| 141 | Modulating the differentiation status of ex vivo-cultured anti-tumor T cells using cytokine cocktails. *Cancer Immunology, Immunotherapy*, **2013**, 62, 727-36 | 7.4 | 71 |
| 140 | Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma. *Ophthalmology*, **2009**, 116, 981-989.e1 | 7.3 | 70 |

| | | | |
|---|---|---|---|
| 139 | Lineage relationship of CD8(+) T cell subsets is revealed by progressive changes in the epigenetic landscape. *Cellular and Molecular Immunology*, **2016**, 13, 502-13 | 15.4 | 70 |
| 138 | Nutrient Competition: A New Axis of Tumor Immunosuppression. *Cell*, **2015**, 162, 1206-8 | 56.2 | 69 |
| 137 | T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy. *Journal of Clinical Investigation*, **2019**, 129, 1551-1565 | 15.9 | 69 |
| 136 | Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma. *Clinical Cancer Research*, **2003**, 9, 2973-80 | 12.9 | 68 |
| 135 | Clinical Scale Zinc Finger Nuclease-mediated Gene Editing of PD-1 in Tumor Infiltrating Lymphocytes for the Treatment of Metastatic Melanoma. *Molecular Therapy*, **2015**, 23, 1380-1390 | 11.7 | 67 |
| 134 | Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies. *Journal of Immunotherapy*, **2011**, 34, 343-52 | 5 | 65 |
| 133 | Both CD4 and CD8 T cells mediate equally effective in vivo tumor treatment when engineered with a highly avid TCR targeting tyrosinase. *Journal of Immunology*, **2010**, 184, 5988-98 | 5.3 | 65 |
| 132 | Metabolic reprograming of anti-tumor immunity. *Current Opinion in Immunology*, **2017**, 46, 14-22 | 7.8 | 63 |
| 131 | Induction of CD4+ T cell-dependent antitumor immunity by TAT-mediated tumor antigen delivery into dendritic cells. *Journal of Clinical Investigation*, **2002**, 109, 1463-1470 | 15.9 | 63 |
| 130 | Cancer vaccines: progress reveals new complexities. *Journal of Clinical Investigation*, **2002**, 110, 289-294 | 15.9 | 62 |
| 129 | Apoptosis is essential for the increased efficacy of alphaviral replicase-based DNA vaccines. *Vaccine* , **2004**, 22, 1537-44 | 4.1 | 61 |
| 128 | Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model. *JCI Insight*, **2018**, 3, | 9.9 | 61 |
| 127 | Natural variation of the expression of HLA and endogenous antigen modulates CTL recognition in an in vitro melanoma model. *International Journal of Cancer*, **1999**, 80, 781-90 | 7.5 | 60 |
| 126 | Programming CD8+ T cells for effective immunotherapy. *Current Opinion in Immunology*, **2006**, 18, 363-70 | 9.8 | 59 |
| 125 | The effects of euglycemic hyperinsulinemia and amino acid infusion on regional and whole body glucose disposal in man. *Metabolism: Clinical and Experimental*, **1991**, 40, 59-65 | 12.7 | 59 |
| 124 | The transcription factor c-Myb regulates CD8 T cell stemness and antitumor immunity. *Nature Immunology*, **2019**, 20, 337-349 | 19.1 | 57 |
| 123 | Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in mice. *Cancer Immunology, Immunotherapy*, **2011**, 60, 671-83 | 7.4 | 55 |
| 122 | Collapse of the tumor stroma is triggered by IL-12 induction of Fas. *Molecular Therapy*, **2013**, 21, 1369-77 | 11.7 | 54 |

| | | | |
|---|---|---|---|
| 121 | T cell-tumor cell: a fatal interaction?. *Cancer Immunology, Immunotherapy*, **1998**, 47, 65-71 | 7.4 | 54 |
| 120 | T-cell receptor gene therapy of established tumors in a murine melanoma model. *Journal of Immunotherapy*, **2008**, 31, 1-6 | 5 | 54 |
| 119 | Countering the 'counterattack' hypothesis. *Nature Medicine*, **2001**, 7, 259 | 50.5 | 54 |
| 118 | Identification of a CD11b+/Gr-1+/CD31+ myeloid progenitor capable of activating or suppressing CD8+T cells. *Blood*, **2000**, 96, 3838-3846 | 2.2 | 54 |
| 117 | Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma. *Journal of Immunotherapy*, **2003**, 26, 385-93 | 5 | 53 |
| 116 | HLA associations in the antitumor response against malignant melanoma. *Journal of Immunotherapy*, **1995**, 18, 242-52 | 5 | 53 |
| 115 | Pharmacologic induction of CD8+ T cell memory: better living through chemistry. *Science Translational Medicine*, **2009**, 1, 11ps12 | 17.5 | 52 |
| 114 | CTLA-4 dysregulation of self/tumor-reactive CD8+ T-cell function is CD4+ T-cell dependent. *Blood*, **2006**, 108, 3818-23 | 2.2 | 51 |
| 113 | Poor immunogenicity of a self/tumor antigen derives from peptide-MHC-I instability and is independent of tolerance. *Journal of Clinical Investigation*, **2004**, 114, 551-9 | 15.9 | 51 |
| 112 | A cleavage product of Polycystin-1 is a mitochondrial matrix protein that affects mitochondria morphology and function when heterologously expressed. *Scientific Reports*, **2018**, 8, 2743 | 4.9 | 49 |
| 111 | Mining the mutanome: developing highly personalized Immunotherapies based on mutational analysis of tumors **2013**, 1, 11 | | 49 |
| 110 | Multi-phenotype CRISPR-Cas9 Screen Identifies p38 Kinase as a Target for Adoptive Immunotherapies. *Cancer Cell*, **2020**, 37, 818-833.e9 | 24.3 | 48 |
| 109 | Moving T memory stem cells to the clinic. *Blood*, **2013**, 121, 567-8 | 2.2 | 48 |
| 108 | Identification of a Kb-restricted CTL epitope of beta-galactosidase: potential use in development of immunization protocols for "self" antigens. *Methods*, **1997**, 12, 117-23 | 4.6 | 48 |
| 107 | Glucocorticoids do not inhibit antitumor activity of activated CD8+ T cells. *Journal of Immunotherapy*, **2005**, 28, 517-24 | 5 | 48 |
| 106 | The stoichiometric production of IL-2 and IFN-□mRNA defines memory T cells that can self-renew after adoptive transfer in humans. *Science Translational Medicine*, **2012**, 4, 149ra120 | 17.5 | 47 |
| 105 | Evaluation of prime/boost regimens using recombinant poxvirus/tyrosinase vaccines for the treatment of patients with metastatic melanoma. *Clinical Cancer Research*, **2006**, 12, 2526-37 | 12.9 | 47 |
| 104 | Autoimmunity and the Immunotherapy of Cancer: Targeting the "Self" to Destroy the "Other". *Critical Reviews in Immunology*, **2000**, 20, 18 | 1.8 | 47 |

| | | | |
|---|---|---|---|
| 103 | Developing recombinant and synthetic vaccines for the treatment of melanoma. *Current Opinion in Oncology*, **1999**, 11, 50-7 | 4.2 | 46 |
| 102 | Sensitization of B16 tumor cells with a CXCR4 antagonist increases the efficacy of immunotherapy for established lung metastases. *Molecular Cancer Therapeutics*, **2006**, 5, 2592-9 | 6.1 | 44 |
| 101 | Novel "Elements" of Immune Suppression within the Tumor Microenvironment. *Cancer Immunology Research*, **2017**, 5, 426-433 | 12.5 | 43 |
| 100 | Ribosomal Proteins Regulate MHC Class I Peptide Generation for Immunosurveillance. *Molecular Cell*, **2019**, 73, 1162-1173.e5 | 17.6 | 42 |
| 99 | The in vivo expansion rate of properly stimulated transferred CD8+ T cells exceeds that of an aggressively growing mouse tumor. *Cancer Research*, **2006**, 66, 1132-8 | 10.1 | 42 |
| 98 | Bedside to bench and back again: how animal models are guiding the development of new immunotherapies for cancer. *Journal of Leukocyte Biology*, **2004**, 76, 333-7 | 6.5 | 42 |
| 97 | Preclinical Evaluation of Chimeric Antigen Receptors Targeting CD70-Expressing Cancers. *Clinical Cancer Research*, **2017**, 23, 2267-2276 | 12.9 | 41 |
| 96 | Cancer immunotherapy. *New England Journal of Medicine*, **2008**, 359, 1072 | 59.2 | 41 |
| 95 | Type I Interferons are essential for the efficacy of replicase-based DNA vaccines. *Vaccine*, **2006**, 24, 5110-8 | 4.1 | 41 |
| 94 | In vitro generated anti-tumor T lymphocytes exhibit distinct subsets mimicking in vivo antigen-experienced cells. *Cancer Immunology, Immunotherapy*, **2011**, 60, 739-49 | 7.4 | 40 |
| 93 | Locus-specific analysis of human leukocyte antigen class I expression in melanoma cell lines. *Journal of Immunotherapy*, **1994**, 16, 13-23 | 5 | 39 |
| 92 | The transcription factor BACH2 promotes tumor immunosuppression. *Journal of Clinical Investigation*, **2016**, 126, 599-604 | 15.9 | 39 |
| 91 | GILT accelerates autoimmunity to the melanoma antigen tyrosinase-related protein 1. *Journal of Immunology*, **2010**, 185, 2828-35 | 5.3 | 38 |
| 90 | Interleukin-10 enhances the therapeutic effectiveness of a recombinant poxvirus-based vaccine in an experimental murine tumor model. *Journal of Immunotherapy*, **1999**, 22, 489-96 | 5 | 35 |
| 89 | Antigen Experienced T Cells from Peripheral Blood Recognize p53 Neoantigens. *Clinical Cancer Research*, **2020**, 26, 1267-1276 | 12.9 | 33 |
| 88 | The kinase DYRK1A reciprocally regulates the differentiation of Th17 and regulatory T cells. *ELife*, **2015**, 4, | 8.9 | 33 |
| 87 | Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers. *Blood*, **2008**, 112, 4746-54 | 2.2 | 32 |
| 86 | Fas/CD95 prevents autoimmunity independently of lipid raft localization and efficient apoptosis induction. *Nature Communications*, **2016**, 7, 13895 | 17.4 | 32 |

| | | | |
|---|---|---|---|
| 85 | Viral sequestration of antigen subverts cross presentation to CD8(+) T cells. *PLoS Pathogens*, **2009**, 5, e1000457 | 7.6 | 31 |
| 84 | Multimodel preclinical platform predicts clinical response of melanoma to immunotherapy. *Nature Medicine*, **2020**, 26, 781-791 | 50.5 | 29 |
| 83 | Reprogramming antitumor immunity. *Trends in Immunology*, **2014**, 35, 178-85 | 14.4 | 29 |
| 82 | Microbiota modulation of myeloid cells in cancer therapy. *Cancer Immunology Research*, **2015**, 3, 103-9 | 12.5 | 28 |
| 81 | Altered CD8(+) T-cell responses when immunizing with multiepitope peptide vaccines. *Journal of Immunotherapy*, **2006**, 29, 224-31 | 5 | 28 |
| 80 | Cross-priming utilizes antigen not available to the direct presentation pathway. *Immunology*, **2006**, 119, 63-73 | 7.8 | 27 |
| 79 | Host conditioning with IL-1 improves the antitumor function of adoptively transferred T cells. *Journal of Experimental Medicine*, **2019**, 216, 2619-2634 | 16.6 | 26 |
| 78 | Programming tumor-reactive effector memory CD8+ T cells in vitro obviates the requirement for in vivo vaccination. *Blood*, **2009**, 114, 1776-83 | 2.2 | 26 |
| 77 | Transcriptional profiles reveal a stepwise developmental program of memory CD8(+) T cell differentiation. *Vaccine*, **2015**, 33, 914-23 | 4.1 | 25 |
| 76 | Generation of Tumor Antigen-Specific iPSC-Derived Thymic Emigrants Using a 3D Thymic Culture System. *Cell Reports*, **2018**, 22, 3175-3190 | 10.6 | 25 |
| 75 | Assumptions of the tumor 'escape' hypothesis. *Seminars in Cancer Biology*, **2002**, 12, 81-6 | 12.7 | 25 |
| 74 | Cancer vaccines: progress reveals new complexities. *Journal of Clinical Investigation*, **2002**, 110, 289-94 | 15.9 | 25 |
| 73 | Does IL-17 promote tumor growth?. *Blood*, **2009**, 114, 231-2 | 2.2 | 24 |
| 72 | MHC class I and class II presentation of tumor antigen in retrovirally and adenovirally transduced dendritic cells. *Cancer Gene Therapy*, **2002**, 9, 946-50 | 5.4 | 24 |
| 71 | Induction of CD4(+) T cell-dependent antitumor immunity by TAT-mediated tumor antigen delivery into dendritic cells. *Journal of Clinical Investigation*, **2002**, 109, 1463-70 | 15.9 | 24 |
| 70 | Increased frequency of suppressive regulatory T cells and T cell-mediated antigen loss results in murine melanoma recurrence. *Journal of Immunology*, **2012**, 189, 767-76 | 5.3 | 23 |
| 69 | Transfectant influenza A viruses are effective recombinant immunogens in the treatment of experimental cancer. *Virology*, **1998**, 249, 89-97 | 3.6 | 23 |
| 68 | Anti-tumor activity of cytotoxic T lymphocytes elicited with recombinant and synthetic forms of a model tumor-associated antigen. *Journal of Immunotherapy*, **1995**, 18, 139-46 | 5 | 23 |

| | | | |
|---|---|---|---|
| 67 | Retroviral transduction of interferon-gamma cDNA into a nonimmunogenic murine fibrosarcoma: generation of T cells in draining lymph nodes capable of treating established parental metastatic tumor. *Cancer Immunology, Immunotherapy*, **1993**, 37, 286-92 | 7.4 | 23 |
| 66 | Type I cytokines synergize with oncogene inhibition to induce tumor growth arrest. *Cancer Immunology Research*, **2015**, 3, 37-47 | 12.5 | 22 |
| 65 | Different adjuvanticity of incomplete freund's adjuvant derived from beef or vegetable components in melanoma patients immunized with a peptide vaccine. *Journal of Immunotherapy*, **2010**, 33, 626-9 | 5 | 22 |
| 64 | Normal tissue depresses while tumor tissue enhances human T cell responses in vivo to a novel self/tumor melanoma antigen, OA1. *Journal of Immunology*, **2003**, 170, 1579-85 | 5.3 | 21 |
| 63 | STING agonist promotes CAR T cell trafficking and persistence in breast cancer. *Journal of Experimental Medicine*, **2021**, 218, | 16.6 | 21 |
| 62 | DNA vaccines and apoptosis: to kill or not to kill?. *Journal of Clinical Investigation*, **2003**, 112, 22-24 | 15.9 | 20 |
| 61 | Expression of a "self-"antigen by human tumor cells enhances tumor antigen-specific CD4(+) T-cell function. *Cancer Research*, **2002**, 62, 5144-7 | 10.1 | 20 |
| 60 | Antisense targeting of CD47 enhances human cytotoxic T-cell activity and increases survival of mice□bearing B16 melanoma when combined with anti-CTLA4 and tumor irradiation. *Cancer Immunology, Immunotherapy*, **2019**, 68, 1805-1817 | 7.4 | 19 |
| 59 | Recognition of neuroectodermal tumors by melanoma-specific cytotoxic T lymphocytes: evidence for antigen sharing by tumors derived from the neural crest. *Cancer Immunology, Immunotherapy*, **1994**, 39, 73-83 | 7.4 | 19 |
| 58 | An effective mouse model for adoptive cancer immunotherapy targeting neoantigens. *JCI Insight*, **2019**, 4, | 9.9 | 19 |
| 57 | Double or nothing on cancer immunotherapy. *Nature Biotechnology*, **2013**, 31, 33-4 | 44.5 | 18 |
| 56 | Transplantation of mouse HSCs genetically modified to express a CD4-restricted TCR results in long-term immunity that destroys tumors and initiates spontaneous autoimmunity. *Journal of Clinical Investigation*, **2010**, 120, 4273-88 | 15.9 | 18 |
| 55 | Genome-wide Screens Identify Lineage- and Tumor-Specific Genes Modulating MHC-I- and MHC-II-Restricted Immunosurveillance of Human Lymphomas. *Immunity*, **2021**, 54, 116-131.e10 | 32.3 | 18 |
| 54 | Identification of the genomic insertion site of Pmel-1 TCR□and □transgenes by next-generation sequencing. *PLoS ONE*, **2014**, 9, e96650 | 3.7 | 17 |
| 53 | Permissivity of the NCI-60 cancer cell lines to oncolytic Vaccinia Virus GLV-1h68. *BMC Cancer*, **2011**, 11, 451 | 4.8 | 17 |
| 52 | High-avidity autoreactive CD4+ T cells induce host CTL, overcome T(regs) and mediate tumor destruction. *Journal of Immunotherapy*, **2009**, 32, 677-88 | 5 | 17 |
| 51 | Mg regulation of kinase signaling and immune function. *Journal of Experimental Medicine*, **2019**, 216, 1828-1842 | 16.6 | 16 |
| 50 | Enhanced efficacy and limited systemic cytokine exposure with membrane-anchored interleukin-12 T-cell therapy in murine tumor models **2020**, 8, | | 15 |

| | | | |
|---|---|---|---|
| 49 | A "big data" view of the tumor "immunome". *Immunity*, **2013**, 39, 631-2 | 32.3 | 15 |
| 48 | Mouse model for pre-clinical study of human cancer immunotherapy. *Current Protocols in Immunology*, **2015**, 108, 20.1.1-20.1.43 | 4 | 15 |
| 47 | Reply to: Catenin does not regulate memory T cell phenotype *Nature Medicine*, **2010**, 16, 514-515 | 50.5 | 15 |
| 46 | Can antitumor immunity help to explain "oncogene addiction"?. *Cancer Cell*, **2010**, 18, 403-5 | 24.3 | 15 |
| 45 | TSCOT+ thymic epithelial cell-mediated sensitive CD4 tolerance by direct presentation. *PLoS Biology*, **2008**, 6, e191 | 9.7 | 15 |
| 44 | Reply to "Cancer vaccines: pessimism in check". *Nature Medicine*, **2004**, 10, 1279-1280 | 50.5 | 15 |
| 43 | Constitutive Lck Activity Drives Sensitivity Differences between CD8+ Memory T Cell Subsets. *Journal of Immunology*, **2016**, 197, 644-54 | 5.3 | 14 |
| 42 | Toll-like receptor agonist therapy can profoundly augment the antitumor activity of adoptively transferred CD8(+) T cells without host preconditioning **2016**, 4, 6 | | 14 |
| 41 | Big bang theory of stem-like T cells confirmed. *Blood*, **2014**, 124, 476-7 | 2.2 | 14 |
| 40 | IFN-gamma-receptor signaling ameliorates transplant vasculopathy through attenuation of CD8+ T-cell-mediated injury of vascular endothelial cells. *European Journal of Immunology*, **2010**, 40, 733-43 | 6.1 | 14 |
| 39 | An engineered IL-2 partial agonist promotes CD8 T cell stemness. *Nature*, **2021**, 597, 544-548 | 50.4 | 14 |
| 38 | Silencing stemness in T cell differentiation. *Science*, **2018**, 359, 163-164 | 33.3 | 13 |
| 37 | Immunologic ignorance of vascular endothelial cells expressing minor histocompatibility antigen. *Blood*, **2008**, 111, 4588-95 | 2.2 | 13 |
| 36 | The next wave of recombinant and synthetic anticancer vaccines. *Seminars in Cancer Biology*, **1995**, 6, 337-47 | 12.7 | 13 |
| 35 | ASXL3 Is a Novel Pluripotency Factor in Human Respiratory Epithelial Cells and a Potential Therapeutic Target in Small Cell Lung Cancer. *Cancer Research*, **2017**, 77, 6267-6281 | 10.1 | 12 |
| 34 | The Cish SH2 domain is essential for PLC-1 regulation in TCR stimulated CD8 T cells. *Scientific Reports*, **2018**, 8, 5336 | 4.9 | 11 |
| 33 | Memoirs of a reincarnated T cell. *Cell Stem Cell*, **2013**, 12, 6-8 | 18 | 11 |
| 32 | Generation of polyclonal rabbit antisera to mouse melanoma associated antigens using gene gun immunization. *Journal of Immunological Methods*, **1998**, 214, 51-62 | 2.5 | 11 |

| | | | |
|---|---|---|---|
| 31 | The power and pitfalls of IL-12. *Blood*, **2012**, 119, 4096-7 | 2.2 | 10 |
| 30 | Strength in Numbers: Identifying Neoantigen Targets for Cancer Immunotherapy. *Cell*, **2020**, 183, 591-593 | 36.2 | 10 |
| 29 | Dose-dependent and schedule-dependent effects of interleukin-12 on antigen-specific CD8 responses. *Journal of Interferon and Cytokine Research*, **2000**, 20, 589-96 | 3.5 | 9 |
| 28 | Use of standard criteria for assessment of cancer vaccines. *Lancet Oncology, The*, **2005**, 6, 3-4 | 21.7 | 9 |
| 27 | Antigen-specific tumor vaccine efficacy in vivo against prostate cancer with low class I MHC requires competent class II MHC. *Prostate*, **2002**, 53, 183-91 | 4.2 | 8 |
| 26 | DNA vaccines and apoptosis: to kill or not to kill?. *Journal of Clinical Investigation*, **2003**, 112, 22-4 | 15.9 | 8 |
| 25 | Lineage relationship of CD8+ T cell subsets is revealed by progressive changes in the epigenetic landscape. *Cellular and Molecular Immunology*, **2015**, | 15.4 | 7 |
| 24 | Antitumor efficacy of tumor-antigen-encoding recombinant poxvirus immunization in Dunning rat prostate cancer: implications for clinical genetic vaccine development. *World Journal of Urology*, **2000**, 18, 136-42 | 4 | 7 |
| 23 | Arginine Arms T Cells to Thrive and Survive. *Cell Metabolism*, **2016**, 24, 647-648 | 24.6 | 6 |
| 22 | Polymeric structure and host Toll-like receptor 4 dictate immunogenicity of NY-ESO-1 antigen in vivo. *Journal of Biological Chemistry*, **2011**, 286, 37077-84 | 5.4 | 6 |
| 21 | The multiple uses of viruses for studying antigen processing. *Seminars in Virology*, **1993**, 4, 109-116 | | 6 |
| 20 | HPV-targeted tumor-infiltrating lymphocytes for cervical cancer.. *Journal of Clinical Oncology*, **2014**, 32, LBA3008-LBA3008 | 2.2 | 6 |
| 19 | Hierarchy, Tolerance, and Dominance in the Antitumor T-Cell Response. *Journal of Immunotherapy*, **2001**, 24, 193-194 | 5 | 6 |
| 18 | Cancer vaccines '98: a reductionistic approach. Bethesda, MD, USA, 27-28 April 1998. *Trends in Molecular Medicine*, **1998**, 4, 327 | | 5 |
| 17 | Poxviruses as vectors for cancer immunotherapy **2000**, 47-61 | | 5 |
| 16 | Identification of Small Molecule Enhancers of Immunotherapy for Melanoma. *Scientific Reports*, **2020**, 10, 5688 | 4.9 | 4 |
| 15 | Targeting Akt in cell transfer immunotherapy for cancer. *OncoImmunology*, **2016**, 5, e1014776 | 7.2 | 4 |
| 14 | Highlights of the society for immunotherapy of cancer (SITC) 27th annual meeting **2013**, 1, | | 4 |

| | | | |
|---|---|---|---|
| 13 | Internal checkpoint regulates T cell neoantigen reactivity and susceptibility to PD1 blockade | | 4 |
| 12 | Customizing Functionality and Payload Delivery for Receptor-Engineered T Cells. *Cell*, **2016**, 167, 304-306 | 36.2 | 4 |
| 11 | Using Human Induced Pluripotent Stem Cells for the Generation of Tumor Antigen-specific T Cells. *Journal of Visualized Experiments*, **2019**, | 1.6 | 2 |
| 10 | Next generation immunotherapy: enhancing stemness of polyclonal T cells to improve anti-tumor activity. *Current Opinion in Immunology*, **2021**, 74, 39-45 | 7.8 | 2 |
| 9 | A Three-dimensional Thymic Culture System to Generate Murine Induced Pluripotent Stem Cell-derived Tumor Antigen-specific Thymic Emigrants. *Journal of Visualized Experiments*, **2019**, | 1.6 | 1 |
| 8 | 141 The Role of T Memory Stem Cells. *Journal of Acquired Immune Deficiency Syndromes (1999)*, **2012**, 59, 59 | 3.1 | 1 |
| 7 | Internal Checkpoint Regulates T Cell Neoantigen Reactivity and Susceptibility to PD1 Blockade. *SSRN Electronic Journal*, | 1 | 1 |
| 6 | Genome-wide Screens Identify Lineage- and Tumor Specific-Genes Modulating MHC-I and MHC-II Immunosurveillance in Human Lymphomas | | 1 |
| 5 | Natural variation of the expression of HLA and endogenous antigen modulates CTL recognition in an In vitro melanoma model **1999**, 80, 781 | | 1 |
| 4 | Multiply restimulated human thymic regulatory T cells express distinct signature regulatory T-cell transcription factors without evidence of exhaustion. *Cytotherapy*, **2021**, 23, 704-714 | 4.8 | 0 |
| 3 | 5-AZA-2?-Deoxycytidine in Cancer Immunotherapy: A Mouse to Man Story. *Cancer Research*, **2007**, 67, 2901-2901 | 10.1 | |
| 2 | Partly MHC Matched Allogeneic Tumor Specific T Cells Mediate Tumor Regression without Inducing GVHD in Immunosuppressed Host.. *Blood*, **2006**, 108, 5210-5210 | 2.2 | |
| 1 | Treatment of Established B16 Murine Melanoma Tumors with Tyrp-1 Specific CD4+ Lymphocytes.. *Blood*, **2006**, 108, 3688-3688 | 2.2 | |